Board MeetingApr 29, 2026, 04:32 PM
TARS to Host Q1 2026 Earnings Call & Corporate Update May 6
AI Summary
Tarsus Pharmaceuticals, Inc. announced it will host a live webcast on Wednesday, May 6, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to report its first quarter 2026 financial results and provide a corporate update. A recorded version of the call will be available on the company's website for approximately 90 days. The company is advancing its pipeline, including XDEMVY for Demodex blepharitis, and TP-04 and TP-05 in Phase 2 for ocular rosacea and Lyme disease prevention, respectively.
Key Highlights
- Tarsus Pharmaceuticals to host Q1 2026 earnings webcast.
- Webcast scheduled for Wednesday, May 6, 2026, at 1:30 p.m. PT / 4:30 p.m. ET.
- Call will cover Q1 2026 financial results and a corporate update.
- Recorded webcast available on company website for approximately 90 days.
- XDEMVY is FDA approved for Demodex blepharitis.
- TP-04 (ocular rosacea) and TP-05 (Lyme disease prevention) are in Phase 2.
Price Impact
More from TARS